Shares of Invitae Co. (NYSE:NVTA – Get Rating) have been given an average recommendation of "Hold" by the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell rating and eight have assigned a hold rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.45.
NVTA has been the subject of a number of research reports. StockNews.com raised shares of Invitae to a "sell" rating in a research note on Friday. SVB Leerink lifted their price objective on shares of Invitae from $2.50 to $3.00 and gave the company a "market perform" rating in a research note on Wednesday, November 9th. Cowen lowered shares of Invitae from an "outperform" rating to a "market perform" rating in a research note on Tuesday, July 26th. Credit Suisse Group initiated coverage on shares of Invitae in a research note on Wednesday, August 24th. They issued an "underperform" rating for the company. Finally, Cowen lifted their price objective on shares of Invitae to $2.80 in a research note on Tuesday, November 15th.
Get Invitae alerts:Invitae Stock Performance
Invitae stock opened at $2.74 on Tuesday. The company has a 50 day moving average price of $2.63 and a 200 day moving average price of $2.95. Invitae has a 52 week low of $1.83 and a 52 week high of $18.87. The company has a quick ratio of 6.18, a current ratio of 6.44 and a debt-to-equity ratio of 10.03.
Invitae (NYSE:NVTA – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The medical research company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.17. The firm had revenue of $133.54 million during the quarter, compared to analyst estimates of $132.80 million. Invitae had a negative net margin of 617.65% and a negative return on equity of 39.04%. On average, equities analysts forecast that Invitae will post -2.43 earnings per share for the current year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Financial Advocates Investment Management bought a new position in shares of Invitae during the 3rd quarter worth about $206,000. Operose Advisors LLC bought a new stake in Invitae in the first quarter valued at about $32,000. AdvisorNet Financial Inc increased its stake in Invitae by 61.0% in the third quarter. AdvisorNet Financial Inc now owns 10,000 shares of the medical research company's stock valued at $25,000 after acquiring an additional 3,788 shares during the period. Credit Agricole S A bought a new stake in Invitae in the third quarter valued at about $25,000. Finally, Clearwater Capital Advisors LLC bought a new stake in Invitae in the first quarter valued at about $82,000. Institutional investors own 88.27% of the company's stock.
About Invitae
(Get Rating)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
Further Reading
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here's What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.